Diego Urrunaga-Pastor, Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Campus 2, Avenida La Fontana 750, La Molina, Lima, Peru. Email:
J Nutr Health Aging. 2022;26(9):856-863. doi: 10.1007/s12603-022-1844-2.
We aimed to evaluate the role of SARC-F and SARC-CalF scores as risk factors for mortality in adults over 60 years of age with cancer of the Centro Médico Naval (CEMENA) in Callao, Peru during 2012-2015.
We performed a secondary analysis of data from a prospective cohort carried out from September 2012 to February 2013 in the Geriatrics Department of CEMENA. The outcome variable was mortality at two years of follow-up, while the exposure variable was the risk of sarcopenia assessed using the SARC-F and SARC-CalF scales. We carried out Cox proportional-hazards models to assess the role of SARC-F and SARC-CalF scores as risk factors for mortality. We estimated crude (cHR) and adjusted (aHR) hazard ratios (HR) with their respective 95% confidence intervals (95%CI). Likewise, we calculated the area under the curve (AUC) of both exposure variables in relation to mortality.
We analyzed data from 922 elderly men with cancer; 43.1% (n=397) were between 60 and 70 years old. 21.5% (n=198) and 45.7% (n=421) were at risk of sarcopenia according to SARC-F and SARC-CalF, respectively, while the incidence of mortality was 22.9% (n=211). In the adjusted Cox regression model, we found that the risk of sarcopenia measured by SARC-F (aHR=2.51; 95%CI: 1.40-2.77) and SARC-CalF (aHR=2.04; 95%CI: 1.55-4.02) was associated with a higher risk of death in older men with cancer. In the diagnostic performance analysis, we found that the AUC for mortality prediction was 0.71 (95%CI: 0.68-0.75) for SARC-F and 0.80 (95%CI: 0.78-0.82) for SARC-CalF.
The risk of sarcopenia evaluated by SARC-F and SARC-CalF scores was associated with an increased risk of mortality in older men with cancer. Both scales proved to be useful and accessible instruments for the identification of groups at risk of mortality.
我们旨在评估 SARC-F 和 SARC-CalF 评分作为秘鲁卡亚俄海军医疗中心(CEMENA) 2012-2015 年 60 岁以上癌症患者死亡风险的因素。
我们对 2012 年 9 月至 2013 年 2 月在 CEMENA 老年科进行的前瞻性队列研究的数据进行了二次分析。结局变量为两年随访时的死亡率,而暴露变量为使用 SARC-F 和 SARC-CalF 量表评估的肌肉减少症风险。我们进行 Cox 比例风险模型来评估 SARC-F 和 SARC-CalF 评分作为死亡率的危险因素的作用。我们估计了粗(cHR)和调整(aHR)风险比(HR)及其各自的 95%置信区间(95%CI)。同样,我们计算了两个暴露变量与死亡率的曲线下面积(AUC)。
我们分析了 922 名患有癌症的老年男性的数据;43.1%(n=397)年龄在 60-70 岁之间。根据 SARC-F 和 SARC-CalF,21.5%(n=198)和 45.7%(n=421)分别有肌肉减少症风险,而死亡率为 22.9%(n=211)。在调整后的 Cox 回归模型中,我们发现 SARC-F 测量的肌肉减少症风险(aHR=2.51;95%CI:1.40-2.77)和 SARC-CalF(aHR=2.04;95%CI:1.55-4.02)与癌症老年男性死亡风险增加相关。在诊断性能分析中,我们发现 SARC-F 对死亡率预测的 AUC 为 0.71(95%CI:0.68-0.75),SARC-CalF 为 0.80(95%CI:0.78-0.82)。
SARC-F 和 SARC-CalF 评分评估的肌肉减少症风险与癌症老年男性的死亡率增加相关。两种量表都被证明是识别死亡风险群体的有用且易于使用的工具。